Role of the microenvironment in ovarian cancer stem cell maintenance

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Pasquier, Jennifer ^a,b   Rafii, Arash ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD24 ANTIGEN; HERMES ANTIGEN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR HOXA9; TRANSFORMING GROWTH FACTOR BETA;

CANCER GROWTH; CANCER MORPHOLOGY; CANCER STEM CELL; CELL DENSITY; DISEASE COURSE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HYPOXIA; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; STROMA; TUMOR MICROENVIRONMENT; ANIMAL; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; OVARIAN NEOPLASMS;

ANIMALS; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84874599849     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/630782     Document Type: Review

References (101)

1. Leminen A., Auranen A., Butzow R., Update on current care guidelines: ovarian cancer. Duodecim 2012 128 12 1300 1301
2. Poveda Velasco A., Casado Herraez A., Cervantes Ruiperez A., Treatment guidelines in ovarian cancer. Clinical and Translational Oncology 2007 9 5 308 316 10.1007/s12094-007-0058-8
3. Stehman F. B., Brady M. F., Thigpen J. T., Rossi E. C., Burger R. A., Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 2012 127 3 495 501
4. Möbus V., Wandt H., Frickhofen N., Bengala C., Champion K., Kimmig R., Ostermann H., Hinke A., Ledermann J. A., Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. Journal of Clinical Oncology 2007 25 27 4187 4193 2-s2.0-34948897497 10.1200/JCO.2006.09.7527 (Pubitemid 47548557)
5. Bookman M. A., Darcy K. M., Clarke-Pearson D., Boothby R. A., Horowitz I. R., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003 21 2 283 290 2-s2.0-0037440042 10.1200/JCO.2003.10.104 (Pubitemid 46606157)
6. Noguera I. R., Sun C. C., Broaddus R. R., Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecologic Oncology 2012 125 640 645
7. Jaaback K., Johnson N., Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2006 1 2-s2.0-33645524716 CD005340
8. Farley J., Ozbun L. L., Birrer M. J., Genomic analysis of epithelial ovarian cancer. Cell Research 2008 18 5 538 548 2-s2.0-43049099384 10.1038/cr.2008.52 (Pubitemid 351630950)
9. Myers E. R., Havrilesky L. J., Kulasingam S. L., Sanders G. D., Cline K. E., Gray R. N., Berchuck A., McCrory D. C., Genomic tests for ovarian cancer detection and management. Evidence Report/Technology Assessment 2006 145 1 100 2-s2.0-35248816072
10. Bell D., Berchuck A., Birrer M., Integrated genomic analyses of ovarian carcinoma. Nature 2011 474 609 615
11. Malek J. A., Mery E., Mahmoud Y. A., Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PloS One 2011 6 12 e28561
12. Alison M. R., Lin W. R., Lim S. M., Nicholson L. J., Cancer stem cells: in the line of fire. Cancer Treatment Reviews 2012 38 6 589 598 10.1016/j.ctrv.2012.03.003
13. Aguilar-Gallardo C., Rutledge E. C., Martinez-Arroyo A. M., Hidalgo J. J., Domingo S., Simon C., Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Reviews 2012 8 994 1010 10.1007/s12015-011-9344-5
14. Burgos-Ojeda D., Rueda B. R., Buckanovich R. J., Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Letters 2012 322 1 7 10.1016/j.canlet.2012.02.002
15. McLean K., Gong Y., Choi Y., Deng N., Yang K., Bai S., Cabrera L., Keller E., McCauley L., Cho K. R., Buckanovich R. J., Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. The Journal of Clinical Investigation 2011 121 8 3206 3219 2-s2.0-79961006281 10.1172/JCI45273
16. Lis R., Touboul C., Raynaud C. M., Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PloS One 2012 7 5 e38340 10.1371/journal.pone.0038340
17. Rafii A., Mirshahi P., Poupot M., Faussat A. M., Simon A., Ducros E., Mery E., Couderc B., Lis R., Capdet J., Bergalet J., Querleu D., Dagonnet F., Fournié J. J., Marie J. P., Pujade-Lauraine E., Favre G., Soria J., Mirshahi M., Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 2008 3 12 2-s2.0-58049204446 10.1371/journal.pone.0003894 e3894
18. Murphy S. K., Targeting ovarian cancer-initiating cells. Anti-Cancer Agents in Medicinal Chemistry 2010 10 2 157 163 2-s2.0-77950838834
19. Naora H., Developmental patterning in the wrong context: the paradox of epithelial ovarian cancers. Cell Cycle 2005 4 8 1033 1035 2-s2.0-25444481792 (Pubitemid 41365358)
20. Gao M. Q., Choi Y. P., Kang S., Youn J. H., Cho N. H., CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010 29 18 2672 2680 2-s2.0-77952240931 10.1038/onc.2010.35
21. Kusumbe A. P., Bapat S. A., Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Research 2009 69 24 9245 9253 2-s2.0-73649107330 10.1158/0008-5472.CAN-09-2802
22. Baba T., Convery P. A., Matsumura N., Whitaker R. S., Kondoh E., Perry T., Huang Z., Bentley R. C., Mori S., Fujii S., Marks J. R., Berchuck A., Murphy S. K., Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009 28 2 209 218 2-s2.0-58249095085 10.1038/onc.2008.374
23. Curley M. D., Therrien V. A., Cummings C. L., Sergent P. A., Koulouris C. R., Friel A. M., Roberts D. J., Seiden M. V., Scadden D. T., Rueda B. O. R., Foster R., CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009 27 12 2875 2883 2-s2.0-73349125059 10.1002/stem.236
24. Kryczek I., Liu S., Roh M., Vatan L., Szeliga W., Wei S., Banerjee M., Mao Y., Kotarski J., Wicha M. S., Liu R., Zou W., Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International Journal of Cancer 2012 130 1 29 39 2-s2.0-79953736251 10.1002/ijc.25967
25. Silva I. A., Bai S., McLean K., Yang K., Griffith K., Thomas D., Ginestier C., Johnston C., Kueck A., Reynolds R. K., Wicha M. S., Buckanovich R. J., Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Research 2011 71 11 3991 4001 2-s2.0-79957917044 10.1158/0008-5472.CAN-10-3175
26. Zhang S., Balch C., Chan M. W., Lai H. C., Matei D., Schilder J. M., Yan P. S., Huang T. H. M., Nephew K. P., Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Research 2008 68 11 4311 4320 2-s2.0-49249091523 10.1158/0008-5472.CAN-08-0364
27. Kurrey N. K., Jalgaonkar S. P., Joglekar A. V., Ghanate A. D., Chaskar P. D., Doiphode R. Y., Bapat S. A., Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009 27 9 2059 2068 2-s2.0-70349859809 10.1002/stem.154
28. Landen C. N. Jr., Goodman B., Katre A. A., Steg A. D., Nick A. M., Stone R. L., Miller L. D., Mejia P. V., Jennings N. B., Gershenson D. M., Bast R. C., Coleman R. L., Lopez-Berestein G., Sood A. K., Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics 2010 9 12 3186 3199 2-s2.0-78650455641 10.1158/1535-7163.MCT-10-0563
29. Luo L., Zeng J., Liang B., Zhao Z., Sun L., Cao D., Yang J., Shen K., Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Experimental and Molecular Pathology 2011 91 2 596 602 2-s2.0-79961119901 10.1016/j.yexmp.2011.06.005
30. Visvader J. E., Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes & Development 2009 23 22 2563 2577 2-s2.0-72749103664 10.1101/gad.1849509
31. Zhang J., Guo X., Chang D. Y., Rosen D. G., Mercado-Uribe I., Liu J., CD133 expression associated with poor prognosis in ovarian cancer. Modern Pathology 2012 25 456 464 10.1038/modpathol.2011.170
32. Steg A. D., Bevis K. S., Katre A. A., Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clinical Cancer Research 2012 18 869 881 10.1158/1078-0432.CCR-11-2188
33. Ferrandina G., Martinelli E., Petrillo M., Prisco M. G., Zannoni G., Sioletic S., Scambia G., CD133 antigen expression in ovarian cancer. BMC Cancer 2009 9, article 221 2-s2.0-68049123605 10.1186/1471-2407-9-221
34. Colmone A., Amorim M., Pontier A. L., Wang S., Jablonski E., Sipkins D. A., Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008 322 5909 1861 1865 2-s2.0-57849108116 10.1126/science.1164390
35. Fuchs E., Tumbar T., Guasch G., Socializing with the neighbors: stem cells and their niche. Cell 2004 116 6 769 778 2-s2.0-1642603951 10.1016/S0092-8674(04)00255-7 (Pubitemid 38410723)
36. Butler J. M., Nolan D. J., Vertes E. L., Varnum-Finney B., Kobayashi H., Hooper A. T., Seandel M., Shido K., White I. A., Kobayashi M., Witte L., May C., Shawber C., Kimura Y., Kitajewski J., Rosenwaks Z., Bernstein I. D., Rafii S., Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010 6 3 251 264 2-s2.0-77449121923 10.1016/j.stem.2010.02.001
37. Barbolina M. V., Moss N. M., Westfall S. D., Liu Y., Burkhalter R. J., Marga F., Forgacs G., Hudson L. G., Stack M. S., Microenvironmental regulation of ovarian cancer metastasis. Cancer Treatment and Research 2009 149 319 334 2-s2.0-66949141951 10.1007/978-0-387-98094-2-15
38. Massague J., TGF- β signaling in development and disease. FEBS Letters 2012 586 14 1833 10.1016/j.febslet.2012.05.030
39. DeNardo D. G., Andreu P., Coussens L. M., Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer and Metastasis Reviews 2010 29 2 309 316 2-s2.0-77954563614 10.1007/s10555-010- 9223-6
40. Karnoub A. E., Dash A. B., Vo A. P., Sullivan A., Brooks M. W., Bell G. W., Richardson A. L., Polyak K., Tubo R., Weinberg R. A., Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007 449 7162 557 563 2-s2.0-34948896045 10.1038/nature06188 (Pubitemid 47525152)
41. Coffelt S. B., Marini F. C., Watson K., Zwezdaryk K. J., Dembinski J. L., LaMarca H. L., Tomchuck S. L., Zu Bentrup K. H., Danka E. S., Henkle S. L., Scandurro A. B., The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proceedings of the National Academy of Sciences of the United States of America 2009 106 10 3806 3811 2-s2.0-62649126972 10.1073/pnas.0900244106
42. Long H., Xie R., Xiang T., Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF- B-mediated MMP-9 upregulation. Stem Cells 2012 30 2309 2319 10.1002/stem.1194
43. Greijer A. E., van der Groep P., Kemming D., Shvarts A., Semenza G. L., Meijer G. A., van de Wiel M. A., Belien J. A. M., van Diest P. J., van der Wall E., Up-regualtion of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor I (HIF-I). The Journal of Pathology 2005 206 3 291 304 2-s2.0-21344438419 10.1002/path.1778 (Pubitemid 40903193)
44. Lara P. C., Lloret M., Clavo B., Apolinario R. M., Henríquez- Hernández L., Bordón E., Fontes F., Rey A., Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiation Oncology 2009 4, article 29 2-s2.0-69049083600 10.1186/1748-717X-4-29
45. Heddleston J. M., Li Z., Lathia J. D., Bao S., Hjelmeland A. B., Rich J. N., Hypoxia inducible factors in cancer stem cells. British Journal of Cancer 2010 102 5 789 795 2-s2.0-77649273107 10.1038/sj.bjc.6605551
46. Liang D., Ma Y., Liu J., The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012 12, article 201 10.1186/1471-2407-12-201
47. Kolenda J., Jensen S. S., Aaberg-Jessen C., Christensen K., Andersen C., Brünner N., Kristensen B. W., Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. Journal of Neuro-Oncology 2011 103 1 43 58 2-s2.0-79959928027 10.1007/s11060-010-0357-8
48. Acharyya S., Oskarsson T., Vanharanta S., A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012 150 1 165 178 10.1016/j.cell.2012.04.042
49. Mitsui H., Shibata K., Suzuki S., Functional interaction between peritoneal mesothelial cells and stem cells of ovarian yolk sac tumor (SC-OYST) in peritoneal dissemination. Gynecologic Oncology 2012 124 303 310 10.1016/j.ygyno.2011.10.006
50. Abelson S., Shamai Y., Berger L., Shouval R., Skorecki K., Tzukerman M., Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer. Stem Cells 2012 30 415 424 10.1002/stem.1029
51. Magee J. A., Ikenoue T., Nakada D., Lee J. Y., Guan K. L., Morrison S. J., Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 2012 11 415 428 10.1016/j.stem.2012.05.026
52. Pardal R., Molofsky A. V., He S., Morrison S. J., Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harbor Symposia on Quantitative Biology 2005 70 177 185 10.1101/sqb.2005.70.057 (Pubitemid 44124870)
53. Quintana E., Shackleton M., Sabel M. S., Fullen D. R., Johnson T. M., Morrison S. J., Efficient tumour formation by single human melanoma cells. Nature 2008 456 7222 593 598 2-s2.0-57349143739 10.1038/nature07567
54. Shank J. J., Yang K., Ghannam J., Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecologic Oncology 2012 127 2 390 397
55. Rattan R., Giri S., Hartmann L. C., Shridhar V., Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. Journal of Cellular and Molecular Medicine 2011 15 1 166 178 2-s2.0-78751692291 10.1111/j.1582-4934.2009.00954.x
56. Rattan R., Graham R. P., Maguire J. L., Giri S., Shridhar V., Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011 13 5 483 491 2-s2.0-79955834631 10.1593/neo.11148
57. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A. B., Shi Q., McLendon R. E., Bigner D. D., Rich J. N., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research 2006 66 16 7843 7848 2-s2.0-33748051406 10.1158/0008-5472.CAN-06-1010 (Pubitemid 44299144)
58. Shen Q., Goderie S. K., Jin L., Karanth N., Sun Y., Abramova N., Vincent P., Pumiglia K., Temple S., Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004 304 5675 1338 1340 2-s2.0-2542626091 10.1126/science.1095505 (Pubitemid 38697433)
59. Cao L., Shao M., Schilder J., Guise T., Mohammad K. S., Matei D., Tissue transglutaminase links TGF- β epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012 31 2521 2534 10.1038/onc.2011.429
60. Brustmann H., Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecologic Oncology 2005 98 3 396 402 2-s2.0-23844447668 10.1016/j.ygyno.2005.04.035 (Pubitemid 41169150)
61. Schmandt R. E., Broaddus R., Lu K. H., Shvartsman H., Thornton A., Malpica A., Sun C., Bodurka D. C., Gershenson D. M., Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor- β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003 98 4 758 764 2-s2.0-0041570242 10.1002/cncr.11561 (Pubitemid 36959272)
62. Chau W. K., Ip C. K., Mak A. S., Lai H. C., Wong A. S., C-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/ β -catenin-ATP-binding cassette G2 signaling. Oncogene. In press
63. 9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. The Journal of Clinical Investigation 2012 122 3603 3617 10.1172/JCI62229
64. Alvero A. B., Fu H. H., Holmberg J., Visintin I., Mor L., Marquina C. C., Oidtman J., Silasi D. A., Mor G., Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009 27 10 2405 2413 2-s2.0-70350243076 10.1002/stem.191
65. Huang R. Y., Chung V. Y., Thiery J. P., Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Current Drug Targets. In press
66. Mani V., Adler E., Briley-Saebo K. C., Bystrup A., Fuster V., Keller G., Fayad Z. A., Serial in vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model of myocardial infarction. Magnetic Resonance in Medicine 2008 60 1 73 81 2-s2.0-46849106527 10.1002/mrm.21642 (Pubitemid 351956611)
67. Singh A., Settleman J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010 29 34 4741 4751 2-s2.0-77956178360 10.1038/onc.2010.215
68. Ansieau S., Bastid J., Doreau A., Morel A. P., Bouchet B. P., Thomas C., Fauvet F., Puisieux I., Doglioni C., Piccinin S., Maestro R., Voeltzel T., Selmi A., Valsesia-Wittmann S., Caron de Fromentel C., Puisieux A., Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008 14 1 79 89 2-s2.0-45849087087 10.1016/j.ccr.2008.06.005 (Pubitemid 351890463)
69. Sarrio D., Franklin C. K., Mackay A., Reis-Filho J. S., Isacke C. M., Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012 30 292 303 10.1002/stem.791
70. Celia-Terrassa T., Meca-Cortes O., Mateo F., Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. The Journal of Clinical Investigation 2012 122 1849 1868 10.1172/JCI59218
71. Jiang H., Lin X., Liu Y., Transformation of epithelial ovarian cancer stem-like cells into mesenchymal lineage via epithelial-mesenchymal transition results in cellular heterogeneity which enables tumor engraftment. Molecular Medicine. In press
72. Steffensen K. D., Alvero A. B., Yang Y., Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of Oncology 2011 2011 12 620523 10.1155/2011/620523
73. Yin G., Alvero A. B., Craveiro V., Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. In press
74. Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F., Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 3983 3988 2-s2.0-0037388204 10.1073/pnas.0530291100 (Pubitemid 36418143)
75. Li C., Heidt D. G., Dalerba P., Burant C. F., Zhang L., Adsay V., Wicha M., Clarke M. F., Simeone D. M., Identification of pancreatic cancer stem cells. Cancer Research 2007 67 3 1030 1037 2-s2.0-33847052127 10.1158/0008-5472.CAN- 06-2030
76. Singh S. K., Hawkins C., Clarke I. D., Squire J. A., Bayani J., Hide T., Henkelman R. M., Cusimano M. D., Dirks P. B., Identification of human brain tumour initiating cells. Nature 2004 432 7015 396 401 2-s2.0-9244241576 10.1038/nature03128 (Pubitemid 39551674)
77. Collins A. T., Habib F. K., Maitland N. J., Neal D. E., Identification and isolation of human prostate epithelial stem cells based on α 2 β 1-integrin expression. Journal of Cell Science 2001 114 21 3865 3872 2-s2.0-0035177262 (Pubitemid 33094701)
78. La Porta C. A., Zapperi S., Human breast and melanoma cancer stem cells biomarkers. Cancer Letters. In press
79. Ginestier C., Hur M. H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C. G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M. S., Dontu G., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007 1 5 555 567 2-s2.0-35848955428 10.1016/j.stem.2007.08.014 (Pubitemid 350056407)
80. Dontu G., Al-Hajj M., Abdallah W. M., Clarke M. F., Wicha M. S., Stem cells in normal breast development and breast cancer. Cell Proliferation 2003 36 supplement 1 59 72 2-s2.0-0347413734 (Pubitemid 37521844)
81. Liu S., Dontu G., Wicha M. S., Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Research 2005 7 3 86 95 2-s2.0-18944407603 10.1186/bcr1021 (Pubitemid 40704127)
82. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., Fiocco R., Foroni C., Dimeco F., Vescovi A., Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Research 2004 64 19 7011 7021 2-s2.0-4944250781 10.1158/0008-5472.CAN-04-1364 (Pubitemid 39331011)
83. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., Tang D. G., Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+ α 2 β 1+ cell population is enriched in tumor-initiating cells. Cancer Research 2007 67 14 6796 6805 2-s2.0-34547128128 10.1158/0008-5472.CAN- 07-0490 (Pubitemid 47105527)
84. Ma S., Chan K. W., Hu L., Lee T. K., Wo J. Y., Ng I. O., Zheng B. J., Guan X. Y., Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007 132 7 2542 2556 2-s2.0-34249980343 10.1053/j.gastro.2007.04.025 (Pubitemid 46890873)
85. O'Brien C. A., Pollett A., Gallinger S., Dick J. E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007 445 7123 106 110 2-s2.0-33846100356 10.1038/nature05372 (Pubitemid 46067310)
86. Ricci-Vitiani L., Lombardi D. G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R., Identification and expansion of human colon-cancer-initiating cells. Nature 2007 445 7123 111 115 2-s2.0-33846095137 10.1038/nature05384 (Pubitemid 46067311)
87. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R., Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation 2008 15 3 504 514 2-s2.0-39449088496 10.1038/sj.cdd.4402283 (Pubitemid 351267301)
88. Pellegatta S., Poliani P. L., Corno D., Menghi F., Ghielmetti F., Suarez-Merino B., Caldera V., Nava S., Ravanini M., Facchetti F., Bruzzone M. G., Finocchiaro G., Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Research 2006 66 21 10247 10252 2-s2.0-33751297619 10.1158/0008-5472.CAN-06-2048 (Pubitemid 44799739)
89. Yao X. H., Ping Y. F., Chen J. H., Xu C. P., Chen D. L., Zhang R., Wang J. M., Bian X. W., Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. The Journal of Pathology 2008 215 4 369 376 2-s2.0-49449117422 10.1002/path.2356
90. Hamerlik P., Lathia J. D., Rasmussen R., Autocrine VEGF-VEGFR2- Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. The Journal of Experimental Medicine 2012 209 507 520 10.1084/jem.20111424
91. Keith B., Simon M. C., Hypoxia-inducible factors, stem cells, and cancer. Cell 2007 129 3 465 472 2-s2.0-34247527730 10.1016/j.cell.2007.04.019 (Pubitemid 46660978)
92. Bhati R., Patterson C., Livasy C. A., Fan C., Ketelsen D., Hu Z., Reynolds E., Tanner C., Moore D. T., Gabrielli F., Perou C. M., Klauber-DeMore N., Molecular characterization of human breast tumor vascular cells. The American Journal of Pathology 2008 172 5 1381 1390 2-s2.0-43449086702 10.2353/ajpath.2008.070988 (Pubitemid 351671550)
93. Lin S. P., Lee Y. T., Yang S. H., Miller S. A., Chiou S. H., Hung M. C., Hung S. C., Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Letters. In press
94. Veeravagu A., Bababeygy S. R., Kalani M. Y. S., Hou L. C., Tse V., The cancer stem cell-vascular niche complex in brain tumor formation. Stem Cells and Development 2008 17 5 859 867 2-s2.0-56749178078 10.1089/scd.2008.0047
95. Takebe N., Warren R. Q., Ivy S. P., Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Research 2011 13 3, article 211 10.1186/bcr2876
96. Nelson C. M., Khauv D., Bissell M. J., Radisky D. C., Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. Journal of Cellular Biochemistry 2008 105 1 25 33 2-s2.0-51849144571 10.1002/jcb.21821
97. Chen C., Wei Y., Hummel M., Hoffmann T. K., Gross M., Kaufmann A. M., Albers A. E., Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011 6 1 2-s2.0-79551522569 10.1371/journal.pone.0016466 e16466
98. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., Kirchner T., Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β -catenin. Cells Tissues Organs 2005 179 1-2 56 65 2-s2.0-22144497081 10.1159/000084509 (Pubitemid 40976289)
99. Klarmann G. J., Hurt E. M., Mathews L. A., Zhang X., Duhagon M. A., Mistree T., Thomas S. B., Farrar W. L., Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clinical & Experimental Metastasis 2009 26 5 433 446 2-s2.0-67349156673 10.1007/s10585-009-9242-2
100. Sarkar F. H., Li Y., Wang Z., Kong D., Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chirurgica 2009 64 5 489 500 2-s2.0-77249117415
101. Jinushi M., Baghdadi M., Chiba S., Yoshiyama H., Regulation of cancer stem cell activities by tumor-associated macrophages. American Journal of Cancer Research 2012 2 529 539